Attenuation of coronary vascular resistance by selective alpha 1-adrenergic blockade in patients with coronary artery disease
MJ Kern,
JD Horowitz,
P Ganz,
J Gaspar,
WS Colucci,
BH Lorell,
WH Barry,
and
GH Mudge Jr
Alpha-adrenergic-mediated coronary vasoconstriction during stress such as cold pressor testing may contribute to myocardial ischemia by increasing coronary vascular resistance in patients with severe coronary artery disease. Nonselective alpha-receptor blockade with phentolamine abolishes both the peripheral and coronary vasoconstriction during cold pressor testing, but causes reflex tachycardia and increased inotropy. To determine the role of selective alpha 1-receptor blockade, the changes in coronary vascular resistance during cold pressor testing were measured in 18 patients with coronary artery disease before and after intravenous administration of 100 mg of trimazosin. Cold pressor testing was performed at a constant paced subanginal heart rate of 95 +/- 5 beats/min (+/- 1 SD). Before trimazosin, cold pressor testing increased mean arterial pressure by 9 +/- 4% (102 +/- 14 to 111 +/- 14 mm Hg, p less than 0.001) with no change in coronary sinus blood flow, but significantly increased coronary vascular resistance by 15 +/- 19% (1.02 +/- 0.46 to 1.15 +/- 0.57 units, p less than 0.05). Five minutes after trimazosin, cold pressor testing increased mean arterial pressure by 6 +/- 5% (p less than 0.001) with a marked attenuation of the increase in coronary vascular resistance (6 +/- 11%, p = NS), which was significantly less than before trimazosin (p less than 0.02). Trimazosin did not increase plasma norepinephrine concentration at rest, suggesting that in the dosage used trimazosin caused selective alpha 1-receptor blockade.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
|
|
 
E. Barbato, F. Piscione, J. Bartunek, G. Galasso, P. Cirillo, G. De Luca, G. Iaccarino, B. De Bruyne, M. Chiariello, and W. Wijns
Role of {beta}2 Adrenergic Receptors in Human Atherosclerotic Coronary Arteries
Circulation,
January 25, 2005;
111(3):
288 - 294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Barbato, J. Bartunek, E. Wyffels, W. Wijns, G. R. Heyndrickx, and B. De Bruyne
Effects of intravenous dobutamineon coronary vasomotion in humans
J. Am. Coll. Cardiol.,
November 5, 2003;
42(9):
1596 - 1601.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Heusch, D. Baumgart, P. Camici, W. Chilian, L. Gregorini, O. Hess, C. Indolfi, and O. Rimoldi
{alpha}-Adrenergic Coronary Vasoconstriction and Myocardial Ischemia in Humans
Circulation,
February 15, 2000;
101(6):
689 - 694.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Baumgart, M. Haude, G. Gorge, F. Liu, J. Ge, C. Große-Eggebrecht, R. Erbel, and G. Heusch
Augmented {{alpha}}-Adrenergic Constriction of Atherosclerotic Human Coronary Arteries
Circulation,
April 27, 1999;
99(16):
2090 - 2097.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Gregorini, J. Marco, M. Kozakova, C. Palombo, G. B. Anguissola, I. Marco, M. Bernies, B. Cassagneau, A. Distante, I. M. Bossi, et al.
{alpha}-Adrenergic Blockade Improves Recovery of Myocardial Perfusion and Function After Coronary Stenting in Patients With Acute Myocardial Infarction
Circulation,
February 2, 1999;
99(4):
482 - 490.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
